HCW Biologics Inc (HCWB) FinancialsHCWBHCW Biologics Inc

Evaluating the bottom line, HCW Biologics Inc maintains a gross margin of -69.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2324.94%, while the net margin is -3849.90%. These profitability ratios, combined with a Return on Equity (ROE) of -580.56%, provide a clear picture of how effectively HCWB converts its operational activities into shareholder value.

In the context of the broader market, HCWB competes directly with industry leaders such as APVO and VIVS. With a market capitalization of $2.31M, it holds a significant position in the sector. When comparing efficiency, HCWB's gross margin of -69.25% stands against APVO's N/A and VIVS's 100.00%. Such benchmarking helps identify whether HCW Biologics Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows a drastic drop in revenue year-over-year, with Q2 2026 revenue at only $135,568 compared to $6,550 in Q1 2025. However, the gross margin for Q1 2026 was an impressive 99.83%, indicating potential for profitability if revenue increases.